28th annual meeting of the German Society for Immunogenetics (DGI)
PIRCHE, one of the ULISES partners, will be sponsor of the 28th annual meeting of DGI.
ULISES is set to develop an immunologic-based treatment strategy where cancer cells are reprogrammed to become “visible” to the patients’ immune system.
According to the statistics from the World Health Organization, cancer is the second leading cause of death globally, counting for approximately 9.6 million deaths in 2018. This figure is expected to increase by 60% by 2040 due to the ageing and increase of the world’s population.
While cancer treatments are currently based on surgical resection of the tumour (if possible), chemotherapy, radiotherapy, target-driven therapies and immunotherapy, ULISES aims to set out an all-new therapeutic strategy based on nanotechnologies.
🩺Our partner Victor Pallaruelo was a guest at 'El laboratorio de JAL' @radio5_rne talking about ULISES 📻Listen here https://t.co/mYBPnpwn1n @JALGUERRERO @EntreProbetas #EUCancerPlan #PancreaticCancer
RT @eu4child: Shining a light on #ChildhoodCancer with #AI - How can we help patients & their families 👧👦? 💡Reinforcing specialised care: t…